David Ricks, Eli Lilly CEO (Evan Vucci/AP Images)

US spends $275M more on Eli Lil­ly's Covid mAb as about half of sup­plies have been ad­min­is­tered so far

Eli Lil­ly said Wednes­day that the US gov­ern­ment has re-upped its sup­ply of the Covid-19 treat­ment bebtelovimab, which is the last mon­o­clon­al an­ti­body or mAb treat­ment left to at­tack this lat­est strain of Omi­cron.

The US will pay $275 mil­lion for 150,000 dos­es of bebtelovimab, which comes out to about $1,833 per dose. Back in Feb­ru­ary, the US bought 600,000 dos­es for $1.08 bil­lion, or about $1,800 per dose.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.